Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032

The BRAF(V600E) mutation, which approaches 50% in human melanomas, constitutively activates pERK and contributes to disease progression. The BRAF(V600E) inhibitor, Vemurafenib (PLX4032), shows promising clinical responses, but resistance to PLX4032 usually develops within a year. Transgenic mouse mo...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Jenkins, Molly H., Steinberg, Shannon M., Alexander, Matthew P., Fisher, Jan L., Ernstoff, Marc S., Turk, Mary Jo, Mullins, David W., Brinckerhoff, Constance E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2014
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3988244/
https://ncbi.nlm.nih.gov/pubmed/24460976
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/pcmr.12220
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller